The Inr Range and Anti-Coagulation

The Inr range for every health except heart valves is 2.0 to 3.0. A bileaflet aortic valve is 2.0 to 3.0 except that it is easier to lump these together with other valves and just say 2.5 to 3.5 for all mechanical valves. On-X may be an irregularity but the jury is still out on that. The healing journal puts out the most ample guidelines for anti-coagulation therapy.

The most recent just came out in June 2008. The most recent Chest guideline for atrial flap say that it should be determined using the same risk-based assessments as would be done for atrial fibrillation. In other words, as far as warfarin is involved a-flutter and a-fib are the same thing. This is a change from a few years ago when a-flutter was determined less likely to cause a stroke.

Afib Stroke

The Chest guidelines rank the evidence on which the committees base their decisions with each decision. The best level of evidence is randomized, double-blinded (neither the someone getting the medication nor the someone giving it to them knows either it is the active drug or the inactive placebo) placebo-controlled studied. The bottom level of evidence is an record detailing what happened to one individual. The level for the atrial flap decision ranks right in the middle (third place out of six ranks).

The Inr Range and Anti-Coagulation

New research finds what does and doesn't help treat AFib.(CARDIOVASCULAR HEALTH): An article from: Healthy Years Best

Rate This Product :

New research finds what does and doesn't help treat AFib.(CARDIOVASCULAR HEALTH): An article from: Healthy Years Overview

This digital document is an article from Healthy Years, published by Belvoir Media Group, LLC on April 1, 2011. The length of the article is 703 words. The page length shown above is based on a typical 300-word page. The article is delivered in HTML format and is available immediately after purchase. You can view it with any web browser.

Citation Details
Title: New research finds what does and doesn't help treat AFib.(CARDIOVASCULAR HEALTH)
Author: Unavailable
Publication:Healthy Years (Magazine/Journal)
Date: April 1, 2011
Publisher: Belvoir Media Group, LLC
Volume: 8 Issue: 4 Page: 3(1)

Distributed by Gale, a part of Cengage Learning

Customer Reviews

*** Product Information and Prices Stored: Dec 30, 2011 21:00:26

I have seen about 3,000 population at seminars on warfarin management. I get the feeling that about 70% atrial fibrillation is about right for a clinic that is open to any someone with any diagnosis. I think the best source is right here. I posted a poll a few years ago about osteoporosis with long-term use. It was not a qoute among population who took warfarin for more than 30 years.

The Inr Range and Anti-CoagulationAtrial Fibrillation & the DECAAF trial--StopAfib.org interviews Dr. Nassir Marrouche (Part 2 or 2) Video Clips. Duration : 4.62 Mins.

In this video interview, Dr. Nassir Marrouche talked about the exciting research he and his team presented at Heart Rhythm 2010 that allows them to personalize atrial fibrillation (AF) treatment. They do catheter ablations and manage stroke prevention based on the amount of atrial fibrosis and atrial remodeling detected by MRI (magnetic resonance imaging). This fibrosis is characterized as Utah 1--4 stages and provides an indication of potential success, what treatments should be used, and the risk of stroke. Dr. Nassir Marrouche is Director of the University of Utah's Electrophysiology Laboratories and Atrial Fibrillation Program, as well as Executive Director of the CARMA (Comprehensive Arrhythmia Research and Management) Center. See our recent article on this research at Personalized Atrial Fibrillation Treatment Using New Method to "Stage" AF at: www.stopafib.org See a full transcript of the interview at: www.stopafib.org Part 1 of 2 can be found at: www.youtube.com

Keywords: Dr. Nassir Marrouche video, stroke prevention, atrial fibrosis, structural remodeling, MRI, Heart Rhythm Society, afib, atrial fibrillation, Stop